Archives for June 28th, 2019
Oasmia changes CEO amid reporting suspicious transactions
Custom Synthesis, Oasmia changes CEO amid reporting suspicious transactions Amid Oasmia’s decision to report certain suspicious transactions that has been made by to company...
ImmuPharma meets primary goal in additional Lupuzor study
Custom Synthesis, ImmuPharma meets primary goal in additional Lupuzor study ImmuPharma has met the primary endpoint in additional study, testing Lupuzor, after requests from...
Glenmark Pharmaceuticals granted Ezetimibe, Simvastatin tablets in USA
Custom Synthesis,Glenmark Pharmaceuticals granted Ezetimibe, Simvastatin tablets in USA Indian Glenmark Pharmaceuticals has been granted final approval by the FDA for Ezetimibe and...
Insys Therapeutics went bankrupt and was fined $1.56 billion
Custom Synthesis, Insys Therapeutics went bankrupt and was fined $ billion Insys Therapeutics was sentenced to $225 million ($ billion) on charges of illegally...
Global TOP Pharmaceutical Enterprises: Overview of Product Performance in 2017-2018
Custom Synthesis, Global TOP Pharmaceutical Enterprises: Overview of Product Performance in 2017-2018 We specialize in Custom Synthesis manufacturing pharmaceutical intermediates with the highest technology...